- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00639171
Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant
December 13, 2023 updated by: Andrzej Krol, State University of New York - Upstate Medical University
Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection
Magnetic Resonance Spectroscopy (MRS) is a novel imaging technique for noninvasive probing of biochemical properties of tissue.
While MRS does not generate images of tumor per se it allows biochemical spectroscopic data to be obtained in vivo from user defined region-of-interest.
In this manner, biochemical information elucidated by MRS can be interpreted in relation to detailed anatomy and images of metabolite distribution can be created.
The aim of MRS is to identify presence and concentration of metabolites characteristic for normal and abnormal (tumor) cellular activities hence allow differential normal tissue from pathological tissue, as well as allow differentiating malignant from benign tumors.
Study Overview
Status
Completed
Conditions
Detailed Description
Recent in vivo studies have reported successful use of 1H and 31P MRS in differentiating between benign and malignant tumors in breast tissue.
These studies demonstrated an increase in the choline metabolite peak that reflects an increase in choline-containing metabolites in 70-80% of breast carcinomas, as compared to 14-18% of benign breast tumors.The objectives would be to determine sensitivity/specificity of MRS in the context of breast CA, We will use normal volunteers to test software and to develop and optimize MR scan sequences prior to or during the testing of target subjects with suspicious breast lesion.
Study Type
Observational
Enrollment (Actual)
3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Subjects will be recruited from two ongoing clinical studies of the breast at SUNY Upstate Medical University.
Description
Inclusion Criteria:
- subjects should have well defined suspicious breast lesion and that will be biopsied
- subjects are to include; varied volunteers with different breast tissue with characteristics such as dense breasts, fibrocystic breasts, "small" breasted and "large" breasted women.
Exclusion Criteria:
- Women of childbearing potential who are not practicing a medically accepted method of birth control should not participate
- Subjects that are pregnant, breast-feeding, should not be able to participate
- Subjects having any of the following metallic devices, will be ineligible to participate in the study: pacemaker, prosthesis, artificial heart valve, coronary artery stents, TENS (Transcutaneous electric nerve stimulator) or other neurological stimulation units and surgical clips.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
|
|
2
Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Andrzej Krol, PhD, State University of New York - Upstate Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2005
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
March 12, 2008
First Submitted That Met QC Criteria
March 19, 2008
First Posted (Estimated)
March 20, 2008
Study Record Updates
Last Update Posted (Estimated)
December 14, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SUNYUMU 4909
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Tumors
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
AmgenCompletedCancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast CancerUnited States, Belgium, France
-
Fudan UniversityEnrolling by invitationBreast Cancers | PET / CT | PIK3CA Mutation-Related Tumors | PI3K Pathway Activated TumorsChina
-
MedSIRNot yet recruitingHER2-positive Breast Cancer | Solid Tumors
-
UNICANCERDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyCompleted
-
Sichuan Provincial People's HospitalCompleted
-
National University Hospital, SingaporeUnknown
-
NSABP Foundation IncRoyal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...CompletedBreast Cancer | Breast Tumors | Breast CarcinomaUnited Kingdom, United States, Canada
-
PfizerCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of BreastIndia
-
Columbia UniversityCompletedBreast Cancer | Breast Tumors | Cancer of BreastUnited States